Paul Gallogly, MD
Retina Specialist · Palm Beach Gardens, FLNPI 1477500791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,810 of the $71,634 with a category attached, or 76.5%. Genentech USA, Inc. accounts for 88.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $26,150 and has fallen 98.5% since, to $393 in 2025. Among retina specialist clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $402.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$64K
- US Retina LLC$3K
- Alimera Sciences, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$589
- Eyepoint US, Inc.$522
- plus $1K from 7 others
Across 3 payments — averaging $343.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$54,81077%
- Travel & lodging$7,91711%
- Food & beverage$5,9118%
- Ownership interest$2,9974%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 56 | $63,508 |
| US Retina LLC | 6 | $2,997 |
| Alimera Sciences, Inc. | 11 | $1,440 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,216 |
| AbbVie(2 entities) | 22 | $589 |
| Eyepoint US, Inc. | 2 | $522 |
| Apellis Pharmaceuticals, Inc. | 11 | $504 |
| Astellas Pharma US Inc | 10 | $349 |
| Novartis | 5 | $161 |
| Rayner Intraocular Lenses Limited | 1 | $125 |
| Ivantis, Inc | 1 | $99 |
| Mallinckrodt Hospital Products Inc. | 1 | $98 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$41,007
- Lucentis$22,006
- Iluvien$1,200
- DEXYCU$362
- Syfovre$268
- YUTIQ$159
- RayOne EMV$125
- RayOne Spheric$125
- RayOne Aspheric$125
- Izervay$123
How this compares
$71,635 in reported general payments places this provider in the 90th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 21 | $9,309 |
| IlevroNepafenac | 14 | $7,566 |
| Prednisolone Acetate | 159 | $6,349 |
| LumiganBimatoprost | 18 | $6,000 |
| Ketorolac Tromethamine | 156 | $2,381 |
| Bromfenac Sodium | 13 | $2,175 |
| MoxifloxacinMoxifloxacin Hcl | 55 | $998 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $838 |
| ErythromycinErythromycin Base | 57 | $545 |
| Acetazolamide | 14 | $422 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $367 |
| Brimonidine Tartrate | 27 | $336 |
| Latanoprost | 20 | $244 |
| Timolol Maleate | 26 | $159 |
| Diclofenac Sodium | 22 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $161 | $7,56614 claims |
| AbbVieLumigan | $589 | $6,00018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Palm Beach Gardens
- Adrian LavinaPalm Beach Gardens$18K
- Philip LairdPalm Beach Gardens$8K
- Mark MichelsPalm Beach Gardens$8K
- Julia NemiroffPalm Beach Gardens$3K
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.